Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 7688 results

  1. Digital front door for people accessing NHS Talking Therapies

    In development [GID-HTE10055] Expected publication date: 23 June 2025

    Health technology evaluations
    In development

  2. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development [GID-TA11386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. LY3209590 for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]

    Awaiting development [GID-TA11645] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. LY3209590 for treating type 2 diabetes in people on daily insulin injections [ID6499]

    Awaiting development [GID-TA11644] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Digital platforms for community based self-management of mild to moderate osteoarthritis and joint pain: Early value assessment

    Awaiting development [GID-HTE10057] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  6. Zuranolone for treating severe postnatal depression ID6431

    In development [GID-TA11356] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Kidney Cancer

    In development [GID-NG10398] Expected publication date: TBC

    NICE guideline
    In development

  8. Tobacco: preventing uptake, promoting quitting and treating dependence - Cytisine for smoking cessation

    In development [GID-NG10427] Expected publication date: 04 February 2025

    NICE guideline
    In development

  9. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 08 January 2025

    Technology appraisal guidance
    In development

  10. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development [GID-TA10832] Expected publication date: 22 January 2025

    Technology appraisal guidance
    In development

  12. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development

  13. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    Awaiting development [GID-TA11633] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Digital support for children and young people with eating disorders:early value assessment

    Awaiting development [GID-HTE10058] Expected publication date: TBC

    Health technology evaluations
    Awaiting development